专利检索 ap:("IMMUSOFT CORPORATION") AND inv:"R. Scott MCIVOR" 第 1 页

1.

发明申请
METHOD TO ACHIEVE EXTENDED EXPRESSION OF DNA INFUSED INTO LIVER 审中-公开

公开(公告)号：US20180185487A1

公开(公告)日：2018-07-05

申请号：US15863740

申请日：2018-01-05

申请人： IMMUSOFT CORPORATION

发明人： R. Scott MCIVOR , Perry B. HACKETT , Jason BELL , Myra Christine URNESS-RUSTEN , Elena ARONOVICH , David W. HUNTER

IPC分类号： A61K47/02 , A61K31/663 , A61K31/353 , A61K48/00 , A61K33/00 , A61K9/00 , A61K38/18 , A61K38/37 , A61K38/48

CPC分类号： A61K47/02 , A61K9/0019 , A61K31/353 , A61K31/663 , A61K33/00 , A61K38/1816 , A61K38/37 , A61K38/4846 , A61K48/0008 , A61K48/0075 , A61K48/0083 , A61K2300/00

摘要： Materials and methods for treating a patient to express a therapeutic agent comprising administering a Kupffer cell-suppressing substance in combination with a vehicle for introducing, into the patient, an exogenous nucleic acid comprising a sequence for expression of the agent.

2.

发明申请
B CELLS FOR IN VIVO DELIVERY OF THERAPEUTIC AGENTS AND DOSAGES THEREOF 有权

公开(公告)号：US20220193129A1

公开(公告)日：2022-06-23

申请号：US16607962

申请日：2018-04-27

申请人： Immusoft Corporation

发明人： Matthew Rein Scholz , Eric J. HERBIG , R. Scott MCIVOR , Rian DE LAAT , Erik Olson

IPC分类号： A61K35/17 , A61K38/47 , A61K38/48 , A61K38/46 , A61K38/45

摘要： The present invention relates to methods for administering autologous and/or allogeneic B cells genetically modified to produce a therapeutic agent, such as a therapeutic protein. Specifically disclosed are methods for administering a single, maximally effective dose of genetically modified B cells and for administering multiple doses of genetically modified B cells. The compositions and methods disclosed herein are useful for the long-term, in vivo delivery of a therapeutic agent.

3.

发明申请
B CELLS GENETICALLY ENGINEERED TO SECRETE FOLLISTATIN AND METHODS OF USING THE SAME TO TREAT FOLLISTATIN-RELATED DISEASES, CONDITIONS, DISORDERS AND TO ENHANCE MUSCLE GROWTH AND STRENGTH 有权

公开(公告)号：US20210047619A1

公开(公告)日：2021-02-18

申请号：US16981618

申请日：2019-03-18

申请人： Immusoft Corporation

发明人： Matthew Rein SCHOLZ , Eric J. HERBIG , R. Scott MCIVOR

IPC分类号： C12N5/0781 , A61K35/16 , A61P21/00 , A61K9/00

摘要： The present invention relates to methods for administering autologous and/or allogeneic B cells genetically modified to produce a therapeutic agent, such as follistatin. Specifically disclosed are methods for administering a single, maximally effective dose of genetically modified B cells and for administering multiple doses of genetically modified B cells that express follistatin. The compositions and methods disclosed herein are useful for the long-term, in vivo delivery of follistatin.